drugset
drugset / Trial / NCT04158583

A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors

NCT04158583 ↗

Phase 1 Terminated 76 enrolled Hoffmann-La Roche
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study was planned to evaluate the safety and tolerability of RO7296682 in participants with advanced solid tumors.

Timeline

Start
2019-12-09
Primary completion
2022-07-21
Completion
2022-07-21

Outcome

Outcome not reported

Stopped: “Halted in order to focus on the ongoing combination of RO7296682 with Atezolizumab, evaluated in study BP42595, as a higher likelihood for efficacy is expected in combination with Atezolizumab as compared to the monotherapy setting.”

Drugs

EvaluationDrugModalityDoseRoute
Subject VOPIKITUG Monoclonal antibody 0.3 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 1 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 2 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 6 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 18 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 20 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 35 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 70 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 100 mg Intravenous
Subject VOPIKITUG Monoclonal antibody 165 mg Intravenous

Indications

cancer